MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


RNS News Service

I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.

Result of AGM

RNS
RNS Number : 3769D
Dechra Pharmaceuticals PLC
27 October 2020
 

 

 

Tuesday, 27 October 2020

 

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

 

 

A poll was held on each of the resolutions proposed at the Annual General Meeting (AGM) of the Company held today

 (27 October 2020).  All resolutions were passed and are as follows:

 

Resolution (No. as noted on proxy form)

 

Total For (includes Discretionary)

Total Against

Total Cast (excludes Withheld)

Withheld (1)


No. of votes

% of vote

No. of votes

% of vote

No. of votes

% of vote

No. of votes

Ordinary Business:








Resolution 1:

To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report

 

80,530,666

99.77%

182,733

0.23%

80,713,399

 

74.67%

907,133

Resolution 2:

To approve the Directors' Remuneration Report

 

81,088,589

99.36%

524,975

0.64%

81,613,564

75.51%

6,968

Resolution 3:

To receive and approve the Directors' Remuneration Policy

 

74,112,644

90.81%

7,501,119

9.19%

81,613,763

75.51%

6,768

Resolution 4:

To declare a final dividend

 

81,611,953

99.99%

8,079

0.01%

81,620,032

75.51%

500

Resolution 5:

To elect Paul Sandland

 

80,408,925

98.52%

1,208,931

1.48%

81,617,856

75.51%

2,676

Resolution 6:

To elect Alison Platt

 

80,875,757

99.09%

742,099

0.91%

81,617,856

75.51%

2,676

Resolution 7:

To re-elect William Anthony Rice

 

71,921,431

88.82%

9,050,362

11.18%

80,971,793

74.91%

648,739

Resolution 8:

To re-elect Ian Page

 

80,588,170

98.74%

1,028,236

1.26%

81,616,406

75.51%

4,126

Resolution 9:

To re-elect Anthony Griffin

 

80,588,674

98.74%

1,027,732

1.26%

81,616,406

75.51%

4,126

Resolution 10:

To re-elect Lisa Bright

 

72,640,656

89.00%

8,975,750

11.00%

81,616,406

75.51%

4,126

Resolution 11:

To re-elect Julian Heslop

 

80,122,785

98.17%

1,492,511

1.83%

81,615,296

75.51%

5,236

Resolution 12:

To re-elect Ishbel Macpherson

 

80,238,227

98.31%

1,379,629

1.69%

81,617,856

75.51%

2,676

Resolution 13:

To re-elect Lawson Macartney

 

80,129,006

98.18%

1,487,380

1.82%

81,616,386

75.51%

4,146

Resolution 14:

To re-appoint PricewaterhouseCoopers as external auditor of the company

 

81,607,914

99.99%

11,668

0.01%

81,619,582

75.51%

950

Resolution 15:

To authorise the Audit Committee to determine the remuneration of the external auditor

 

81,616,178

100.00%

2,944

0.00%

81,619,122

75.51%

1,410

Special Business:








Resolution 16:

To authorise the directors to allot shares to specific limits

 

76,917,382

94.24%

4,701,513

5.76%

81,618,895

75.51%

1,637

Resolution 17:

To disapply the pre-emption rights

 

81,554,619

99.92%

63,753

0.08%

81,618,372

75.51%

2,160

Resolution 18:

To disapply additional pre-emption rights

 

80,907,507

99.13%

710,766

0.87%

81,618,273

75.51%

2,259

Resolution 19:

To authorise the Company to purchase its own shares

 

79,915,307

98.15%

1,509,708

1.85%

81,425,015

75.33%

195,517

Resolution 20:

To authorise the Company to hold any general meeting (other than an AGM) on not less than 14 clear days' notice

 

80,053,146

98.08%

1,566,747

1.92%

81,619,893

75.51%

639

 

Notes:

1.  A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

2.  Resolutions 1 to 16 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

3.  Resolutions 17 to 20 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

4.  Issued Share Capital at meeting date: 108,089,861.

5.  Equiniti, Registrar to the Company, were appointed for the purpose of the Poll taken at the AGM and certify as scrutineer that the result of the Poll is correctly set out above.

 

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

 

For further information, please contact:

Melanie Hall

Company Secretary

Dechra Pharmaceuticals PLC

Telephone: +44 (0) 1606 814 730

Email: corporate.enquiries@dechra.com  

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com .

 

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEALEXAADEFFA